A precision approach to rare kidney disease
Management Team
Our leadership team brings deep experience across rare disease drug development, clinical operations, chemistry, and finance.
Board of Directors
Expertise across rare disease drug development, biotech finance, and life sciences strategy.
Joined Eloxx in April 2021. Previously President, CEO, and director of Zikani Therapeutics, and Interim President & CFO of Progenity. Earlier roles at Adage Capital and McKinsey & Company.
Sumit Aggarwal joined Eloxx as President and Chief Executive Officer in April 2021. He previously served as President, CEO, and a director of Zikani Therapeutics, Inc., where he led the company's transformation into a rare disease and oncology-focused organization. Prior to Zikani, Mr. Aggarwal was interim President and Chief Financial Officer of Progenity, Inc. He has held leadership roles at Adage Capital and McKinsey & Company. Mr. Aggarwal has more than 20 years of experience in pharmaceutical and biotechnology commercial operations, investment management, and management consulting. He holds an M.B.A. with distinction from the Johnson School, Cornell University, and a B.Tech with Honors in Chemical Engineering from IIT Kharagpur.
25+ years in biopharma venture investing. Backed 30+ companies through eight public listings. Portfolio includes Tesaro (GSK), Labrys (Teva), and Trius (Cubist). Co-founder of WoVen: Women Who Venture.
Ms. Kjellson is a General Partner at Canaan Partners, an early-stage venture capital firm focused on biopharmaceutical innovation, and the principal of Pelican Advisory, LLC. Over a 25-year career she has backed more than 30 private companies, navigated over a dozen acquisitions, and supported eight public listings. She currently serves on the boards of Actio Biosciences, Rondo Therapeutics, Tizona Therapeutics, Trishula Therapeutics, and Proxygen. Before Canaan, she was a General Partner at InterWest Partners, where her portfolio included Tesaro (acquired by GSK), Labrys (acquired by Teva), Trius (acquired by Cubist), and Paratek. Ms. Kjellson is co-founder of WoVen: Women Who Venture, a Health Innovators Fellow of the Aspen Institute, and serves on the boards of BIO.org and the Foundation for the National Institutes of Health. She holds a B.A. in Human Biology from Stanford University.
Former General Counsel, IVAX Corporation. On the Eloxx board since May 2014. Director of Red Violet, Cocrystal Pharma, Niagen Bioscience, and Entera Bio.
Steven Rubin has served on the Eloxx board since May 2014. Mr. Rubin is the Executive Vice President — Administration and a Director of OPKO Health, Inc. He previously served as Senior Vice President, General Counsel and Secretary of IVAX Corporation. Mr. Rubin currently serves as a Director of Red Violet, Inc., Cocrystal Pharma, Niagen Bioscience (formerly ChromaDex), and Entera Bio Ltd. He has held numerous prior board roles across the biopharmaceutical sector. Mr. Rubin received a B.A. in Economics from Tulane University and a J.D. from the University of Florida.
25+ years at Genzyme in BD, R&D, general management, and venture capital, most recently managing Genzyme Ventures. CEO & Chairman of Aleta Biotherapeutics. Co-founder of The Termeer Foundation.
Alan Walts joined the Eloxx board in April 2021. Dr. Walts is a Venture Partner with Advent Life Sciences (since 2014), CEO and Chairman of Aleta Biotherapeutics, and co-founder and Executive Chairman of AlphaRose Therapeutics. He is also an independent Director of Neuroelectrics Corp and Artax Biopharma. Dr. Walts has over 25 years of industry experience at Genzyme in business development, strategy, R&D, general management, and venture capital, most recently managing Genzyme Ventures (now Sanofi Ventures). He is also a co-founder and Director of The Termeer Foundation. Dr. Walts received a Ph.D. in chemistry from MIT, conducted post-doctoral research at MIT with Professor Christopher Walsh, and completed the Program for Management Development at Harvard Business School.
Led Spark's 2015 IPO and its $4.3B acquisition by Roche. Oversaw LUXTURNA commercialization — the first FDA-approved gene therapy. Audit Committee Chair at Cullinan Therapeutics (NASDAQ: CGEM) and NextCure (NASDAQ: NXTC).
Mr. Webster is an experienced life sciences board director, former investment banker, and CFO with a proven track record of value creation across all sizes and stages of biopharmaceutical companies. He retired as CFO of Spark Therapeutics (NASDAQ: ONCE) in 2019 following the company's $4.3 billion acquisition by Roche, having led its 2015 IPO, raised approximately $1 billion in equity financings, and participated in the pricing and commercialization of LUXTURNA — the first FDA-approved gene therapy. Previously, he served as CFO of Optimer Pharmaceuticals and Adolor Corporation, both of which were acquired by Cubist Pharmaceuticals. He currently serves as independent director and Audit Committee Chair at Cullinan Therapeutics (NASDAQ: CGEM) and NextCure (NASDAQ: NXTC), and as a director and Audit Committee member of Imvax.